EN | UA
EN | UA

Help Support

Back

Nirsevimab's impact on RSV-related infant hospitalizations explored in latest study

RSV-related infant hospitalizations RSV-related infant hospitalizations
RSV-related infant hospitalizations RSV-related infant hospitalizations

What's new?

Nirsevimab proved effective in averting respiratory syncytial virus-related hospitalizations in infants (aged <12 months).

A study featured in “The New England Journal of Medicine” disclosed that Nirsevimab (a monoclonal antibody) provided protection against hospitalization for respiratory syncytial virus (RSV)-associated lower respiratory tract infection, including very severe cases, in conditions closely resembling real-world settings for infants.

This study led by Simon B. Drysdale and his team explored the safety of Nirsevimab and its effect on hospitalizations for RSV-associated lower respiratory tract infection (RSV-LRTI) when used in healthy infants. Overall, 8058 infants aged 12 months or younger (born at gestational age = minimum 29 weeks), and entering their initial RSV season in Western European countries were allocated in a 1:1 ratio at random. They were either administered with Nirsevimab intramuscular injection (number of infants=4037) or underwent standard care (no intervention) (number of infants=4021) prior to or during the RSV outbreaks.

The primary endpoint was hospitalization due to RSV-LRTI, characterized by both admissions to the hospital and a positive result indicating RSV infection. Acute RSV-LRTI, defined as hospitalization for RSV-LRTI with an oxygen saturation of <90% and the need for supplemental oxygen was considered as the secondary endpoint. The details of Nirsevimab efficacy have been described below (Table 1):

The effectiveness of Nirsevimab against hospitalization for RSV-associated LRTI was 89.6% in France, 74.2% in Germany and 83.4% in the UK. Eighty-six infants (2.1%) in the Nirsevimab group reported therapy-linked adverse events.

Source:

The New England Journal of Medicine

Article:

Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants

Authors:

Simon B Drysdale et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: